KRAS G12D Inhibitor Crystal Forms for Stable Drug Development
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current KRAS inhibitors are ineffective against KRAS G12D mutations, which are prevalent in various cancers, due to the lack of conventional small molecule binding sites and high affinity for guanylic acid, making KRAS a challenging target for drug development.
Innovation Solution
Development of crystal forms of a novel KRAS G12D inhibitor (formula I) with specific X-ray powder diffraction patterns, prepared using various solvents and crystallization methods, ensuring good physical and chemical stability for drug development and storage.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If KRAS protein is targeted for drug development, then inhibition of KRAS G12D mutation can be achieved, but the lack of conventional small molecule binding sites and ultrahigh affinity for guanylic acid makes it extremely difficult to develop effective inhibitors
Solution Approach 1:
The patent changes the chemical structure parameters of the inhibitor molecule by introducing a sulfonamide group and specific substituent patterns (R1-R6 positions) to create compounds that can bind to the KRAS G12D mutation site despite the lack of conventional binding sites. This structural parameter optimization enables effective inhibition while overcoming the natural resistance of KRAS to small molecule binding
2Stability of the object's composition
If crystal forms of the KRAS G12D inhibitor are developed, then physical and chemical stability for drug storage is improved, but multiple crystal forms require extensive characterization and validation
Solution Approach 1:
The patent identifies and characterizes different crystal phases (Crystal Form A and Crystal Form B) of the KRAS G12D inhibitor, each with distinct X-ray powder diffraction patterns. By establishing the specific diffraction characteristics of each crystal form, the patent enables rapid identification and selection of the most stable form for drug development, reducing the time required for stability assessment
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The crystal forms provide stable and effective KRAS G12D inhibitors, potentially treating a wide range of cancers by inhibiting the KRAS G12D mutation, addressing the unmet need in cancer therapy.
Implementation Method 1
KRAS protein has long been considered as an undruggable drug target because it lacks conventional small molecule binding sites on its surface and it is extremely difficult to inhibit due to its ultrahigh affinity for guanylic acid
Implementation Method 2
an X-ray powder diffraction pattern of the crystal form has characteristic peaks at 2θ angles of 9.2, 13.1, 14.5, 16.6, 17.7, and 21.5
Implementation Method 3
an X-ray powder diffraction pattern of the crystal form has characteristic peaks at 2θ angles of 9.2, 13.1, 14.5, 16.6, 17.7, and 21.5
Implementation Method 4
After KRAS is activated, it regulates multiple functions such as cell proliferation, survival, migration, and metabolism through a plurality of downstream signaling pathways represented by RAF-MEK-ERK, PI3K-AKT-mTOR, and TIAM1-RAc
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present disclosure relates to a crystal form of a KRAS G12D inhibitor and a preparation method therefor. Specifically, provided in the present disclosure are crystal forms A, B, C, D, E, F, G, H, I, J, K, L, M, N and O of a compound as represented by formula (I), and a preparation method therefor.